Atea Pharmaceuticals, Inc. (AVIR) has a consensus analyst rating of Hold, based on 4 analysts covering the stock. Of those, 1 recommend buying, 2 recommend holding, and 1 recommend selling.
The analyst consensus price target for AVIR is $6.88, representing a +18.6% upside from the current price of $5.8. Price targets range from a low of $6.88 to a high of $6.88.
